Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

NCT02244112 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02244112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2014
Completion date
July 10, 2019
Enrollment
43 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-central nervous system (cns) malignancies